BioROSA Technologies Inc.

Today Autism is diagnosed based on the presence of behavioral symptoms in early life. There is no blood test that can predict autism or diagnose the challenging condition. Additionally, there are no medical treatments that have been created for autism. BioROSA technologies has the first broad-spectrum blood test performing at 95.2% sensitivity, 91.5% specificity for early detection of autism in infancy and a platform to develop novel treatments.